🔗 Share this article

Given that the US undertakes unprecedented adjustments to its vaccination guidelines, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines in the global health crisis and has zeroed in on alleged deaths following Covid immunization in her brief time at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Schedule

Health officials planned to announce radical revisions to the pediatric immunization program earlier this month, synchronizing the US with the Danish national calendar, sources say – a significant shift that would put the US at odds with a large portion of the world with little proof for benefit. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting specific childhood shot schedules in the US so as to align more in line with Denmark, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

In her initial public appearances, she has kept her attention on immunizations – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

The appointee has no obvious background in drug development, approval processes or management, which has been standard for previous heads of the biologics center. She has been employed at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the requisite experience” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a large organization. She has no expertise in industry regulation.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the generic drug division approves thousands of generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and every single one have to be looked after,” she said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial leadership element to the position, which oversees over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” the former official concluded.

Response and Disputed Programs

Regarding inquiries about Høeg’s credentials and whether this selection indicates more teamwork among agency officials on vaccines, a spokesperson responded that the “inquiries rely on inaccurate assumptions”.

“Her experience aligns with the responsibilities of her role,” the representative said, noting the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s controversial expedited review system, a contentious one-day medication authorization process that reportedly worried her predecessors. “By what process are these drugs being selected for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards laxer oversight of most medications, except for vaccines.”

Established Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if concerning, track record, Howard said. She authored a study using unverified public submissions to assess the frequency of heart inflammation after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the current federal leadership encompassed changing regulations for recently developed shots and ending “unnecessary” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources proposed barring teenage boys from obtaining Covid vaccines.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to retrofit the data in a very misleading, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|